[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506967":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":102,"collaborators":105,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":32,"eligibilityCriteria":115,"healthyVolunteers":111,"sex":116,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":32,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":67,"whyStopped":32,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Chi-Ven treatment","EXPERIMENTAL","Patients receive chidamide and venetoclax treatment",[13],"Drug: Chidamide+venetoclax",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Chidamide+venetoclax","Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28",[9],[21],"Chi-VEN",[23],{"name":24,"affiliation":25,"role":26},"Chun Wang","Zhaxin Hospital, Go Broad Health Care","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Chun Wang, M.D.,","CONTACT","8613386259777",null,"wangchunsh@medmail.com.cn",[35,53,65,84,89],{"facility":36,"status":37,"city":38,"state":39,"zip":32,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"The Affiliated Huai An No 1 Perople's Hospital of NanJing University","NOT_YET_RECRUITING","Huai'an","Jiangsu","China","CN",{"type":43,"coordinates":44},"Point",[45,46],119.01917,33.58861,{"lat":46,"lon":45},[49],{"name":50,"role":30,"phone":51,"phoneExt":32,"email":52},"Liang Yu","8613405509177","yuliangha@163.com",{"facility":54,"status":37,"city":55,"state":56,"zip":32,"country":40,"countryCode":41,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"The First Affiliated Hospital of Nanchang University","Nanchang","Jiangxi",{"type":43,"coordinates":58},[59,60],115.85306,28.68396,{"lat":60,"lon":59},[63],{"name":64,"role":30,"phone":32,"phoneExt":32,"email":32},"Wenhua Zhou",{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":40,"countryCode":41,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Jiong HU","RECRUITING","Shanghai","Shanghai Municipality","200025",{"type":43,"coordinates":72},[73,74],121.45806,31.22222,{"lat":74,"lon":73},[77,81],{"name":78,"role":30,"phone":79,"phoneExt":32,"email":80},"Jiong HU, M.D.,","86-21-64370045","hj10709@rjh.com.cn",{"name":82,"role":30,"phone":79,"phoneExt":32,"email":83},"Ling Wang, M.D.,","cclingjar@163.com",{"facility":25,"status":85,"city":68,"state":69,"zip":32,"country":40,"countryCode":41,"cosmosGeoPoint":86,"geoPoint":88,"contacts":32},"ACTIVE_NOT_RECRUITING",{"type":43,"coordinates":87},[73,74],{"lat":74,"lon":73},{"facility":90,"status":67,"city":91,"state":32,"zip":32,"country":40,"countryCode":41,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"NanFang Hospital","Guangzhou",{"type":43,"coordinates":93},[94,95],113.25,23.11667,{"lat":95,"lon":94},[98],{"name":99,"role":30,"phone":100,"phoneExt":32,"email":101},"Hongsheng Zhou","8618665730280","zhs1@i.smu.edu.cn",{"type":103,"investigatorFullName":66,"investigatorTitle":104,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Head, Blood & Marrow Transplantation Center, Rui Jin Hospital",[106],{"name":107,"class":108},"Shanghai Clinical Research Center","UNKNOWN","100506967","phase-2-treatment-of-chidamide-and-venetoclax-for-retinoic-acid-and-arsenic-resistant-acute-promyelocytic-leukemia-100506967",false,"NCT05881265","Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","Multi-center Phase II Prospective Study for the Treatment of Chidamide and Venetoclax in Patients With All-trans Retinoic Acid (ATRA) and Arsenic (As) Resistant Acute Promyelocytic Leukemia (APL)","Inclusion Criteria:\n\n* Patients with PML-RARα+ APL\n* Patients in non-remission status after treatment of RA combined with As\n* Patients with life expectance \\>=3 months\n* Inform consent provided\n\nExclusion Criteria:\n\n* Patients with incontrollable infection\n* Patients with life-expectancy less than 2 months\n* Patients with abnormal liver (\\>3XN) and renal function (\\>3XN）","ALL","16 Years","70 Years",{"count":120,"type":121},30,"ESTIMATED","INTERVENTIONAL",[124],"PHASE2","Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment. In our pre-clinical study, we found that targeting histone deacetylase inhibitor 3 (HDAC3)degraded PML-RARa oncoprotein and induced differentiation and apoptosis of RA and As resistant APL in vitro and in vivo. In this study, we evaluate the efficacy and feasibility of combination therapy for HDAC3 inhibitor and venetoclax in patients with refractory APL.",[127],"APL",[129],"refractory，APL","2025-02-14",{"date":132,"type":133},"2025-02-18","ACTUAL",{"date":135,"type":133},"2023-05-15",{"date":137,"type":121},"2026-01-01",{"name":5,"class":6},5]